公开(公告)号：US09777020B2

公开(公告)日：2017-10-03

申请号：US14603043

申请日：2015-01-22

Applicant: AbbVie Inc.

Inventor： Robert J. Altenbach ,  Huaqing Liu ,  Bruce Clapham ,  Ana L. Aguirre ,  Marlon Cowart ,  John R. Koenig ,  Kathy Sarris ,  Marc J. Scanio ,  Kerren K. Swinger ,  Anil Vasudevan ,  Clara I. Villamil ,  Kevin R. Woller

IPC: C07D407/12 ,  C07D491/048 ,  C07D491/20 ,  C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D491/107 ,  C07D493/10

CPC classification number: C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D407/12 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D493/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160376240A1

公开(公告)日：2016-12-29

申请号：US15112870

申请日：2015-01-16

Applicant: ABBVIE INC.

Inventor： William Bunnelle ,  Marlon Cowart ,  Irene Drizin ,  John Robert Koenig ,  Marina Pliushchev ,  Marc Scanio

IPC: C07D231/56 ,  C07D405/14 ,  C07D417/14 ,  C07D487/10 ,  C07D403/12 ,  C07D471/04 ,  C07D413/10 ,  C07D401/10 ,  C07D405/12 ,  C07D401/12

CPC classification number: C07D231/56 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/10 ,  C07D417/14 ,  C07D471/04 ,  C07D487/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2，R3，R4，R5，R6和X如说明书中所定义，可用于治疗病症或障碍 由Tropomysin受体激酶（Trk）改变或改善。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US20210047304A1

公开(公告)日：2021-02-18

申请号：US16883713

申请日：2020-05-26

Applicant: AbbVie Inc.

Inventor： Marlon Cowart ,  Steven Fidanze ,  Lisa Hasvold ,  Dachun Liu ,  Keith McDaniel ,  John Pratt ,  George Sheppard ,  Le Wang

IPC: C07D405/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D487/10

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20190382383A1

公开(公告)日：2019-12-19

申请号：US16341352

申请日：2016-10-14

Applicant: AbbVie Inc.

Inventor： Marlon Cowart ,  Steven Fidanze ,  Lisa Hasvold ,  Dachun Liu ,  Keith McDaniel ,  John Pratt ,  George Sheppard ,  Le Wang

IPC: C07D405/12 ,  C07D487/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20150210720A1

公开(公告)日：2015-07-30

申请号：US14603043

申请日：2015-01-22

Applicant: AbbVie Inc.

Inventor： Robert J. Altenbach ,  Huaqing Liu ,  Bruce Clapham ,  Ana L. Aguirre ,  Marlon Cowart ,  John R. Koenig ,  Katerina Sarris ,  Marc J. Scanio ,  Kerren K. Swinger ,  Anil Vasudevan ,  Clara I. Villamil ,  Kevin R. Woller

IPC: C07D519/00 ,  C07D493/10 ,  C07D405/12 ,  C07D491/20 ,  C07D307/83 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D519/00 ,  C07D307/83 ,  C07D405/12 ,  C07D407/12 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D493/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，Z1，Z2和n如说明书中所定义，可用于治疗由Tropomysin受体阻止或改善的病症或病症 激酶（Trk）。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。